{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:48:05Z","timestamp":1789480085513,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess clinical outcomes in patients treated with eculizumab for acute attacks of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed prospectively collected data from the Huashan NMOSD registry cohort, and included patients who received eculizumab within 30 days of attack onset. Eculizumab was administered at 900 mg weekly for four weeks, followed by an eight-week observation period. Primary outcomes included visual acuity and visual field for optic neuritis (ON) and muscle strength, assessed using the Medical Research Council (MRC) scale for longitudinally extensive transverse myelitis (LETM). Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels were also monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine patients (seven with ON, two with LETM) were included. All patients received high-dose intravenous methylprednisolone prior to eculizumab treatment. Following eculizumab, six of the seven ON patients showed significant improvements in visual acuity and visual fields, with five recovering to near-normal or pre-attack vision. Visual field mean deviation improved from \u221222.4 dB to \u22122.0 dB (<jats:italic>p<\/jats:italic> = 0.008). Among LETM patients, one regained substantial lower limb strength (MRC grade 0 to 3 proximally, 4 distally), while the other showed improvement in distal strength (MRC grade 0 to 3). Serum sGFAP decreased from 278.0 to 130 pg\/mL (<jats:italic>p<\/jats:italic> = 0.027), while sNfL levels transiently increased before stabilizing. One LETM patient developed a urinary tract infection, and another had <jats:italic>Klebsiella pneumoniae<\/jats:italic> pneumonia; all infections were effectively treated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Eculizumab may yield favorable outcomes in acute NMOSD attacks, with infection monitoring being particularly important in severe cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1645401","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:30:02Z","timestamp":1758778202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Eculizumab for the acute attack of neuromyelitis optica spectrum disorder"],"prefix":"10.3389","volume":"16","author":[{"given":"Qingqing","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzi","family":"ZhangBao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1090548","article-title":"Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders","volume":"14","author":"Miyamoto","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12132","article-title":"Increased soluble C5b-9 in CSF of neuromyelitis optica","volume":"79","author":"Wang","year":"2014","journal-title":"Scand J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder","volume":"12","author":"Singh","year":"2021","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B16","volume-title":"Standard Logarithmic Vision Chart (GB\/T 11533-2011)","year":"2011"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","article-title":"The OSCAR-IB consensus criteria for retinal OCT quality assessment","volume":"7","author":"Tewarie","year":"2012","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult Scler"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3310\/hta21310","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"B21","article-title":"Rehabilitation results of patients with acute transverse myelitis","volume":"112","author":"Calis","year":"2011","journal-title":"Bratisl Lek Listy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report","volume":"13","author":"Chatterton","year":"2022","journal-title":"Front Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.15082\/jsnt.39.4_731","article-title":"Two cases of anti-aquaporin 4 antibody-positive neuromyelitis optica treated with eculizumab early after relapse","volume":"39","author":"Kaneko","year":"2022","journal-title":"Neurol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.nerep.2024.100213","article-title":"Efficacy of eculizumab in acute refractory pediatric neuromyelitis optica: A case report","volume":"5","author":"Enriquez","year":"2024","journal-title":"Neuroimmunol Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06971-x","article-title":"Eculizumab for a catastrophic relapse in NMOSD: case report","volume":"45","author":"Gorriz","year":"2024","journal-title":"Neurol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.09.001","article-title":"Eculizumab as rescue therapy in a context of dramatic NMOSD attack: Report of two cases","volume":"180","author":"San-Galli","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e73205","DOI":"10.7759\/cureus.73205","article-title":"The efficacy of eculizumab in the acute phase of neuromyelitis optica spectrum disorder: A case series study","volume":"16","author":"Watanabe","year":"2024","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241283650","article-title":"Acute eculizumab treatment in a pediatric patient with AQP4-IgG+ NMOSD","volume":"31","author":"Soni","year":"2025","journal-title":"Mult Scler"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001991","article-title":"Retinal changes after acute and late optic neuritis in aquaporin-4 antibody seropositive NMOSD","volume":"44","author":"Oertel","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.4400","article-title":"Blood-based biomarkers for identifying disease activity in AQP4-igG-positive neuromyelitis optica spectrum disorder","volume":"82","author":"Kim","year":"2025","journal-title":"JAMA Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e213399","DOI":"10.1212\/WNL.0000000000213399","article-title":"Severe relapse after switching from eculizumab to satralizumab in neuromyelitis optica spectrum disorder","volume":"104","author":"Maillart","year":"2025","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104949","article-title":"Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment","volume":"79","author":"Sen","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:30:03Z","timestamp":1758778203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1645401"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1645401","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1645401"}}